Author(s):
Pranjal A. Patil, Divakar R. Patil, Akash S. Jain, Azam Z. Shaikh, Sameer R. Shaikh, S. P. Pawar
Email(s):
pranjalpatel15062@gmail.com
DOI:
10.52711/2349-2988.2025.00032 
Address:
Pranjal A. Patil1, Divakar R. Patil2, Akash S. Jain3, Azam Z. Shaikh2, Sameer R. Shaikh2, S. P. Pawar4.
1B. Pharm. Student, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India.
2Assistant Professor, Department of Pharmaceutics, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India.
3Assistant Professor, Department of Quality Assurance, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India.
4Principal, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 3,
Year - 2025
ABSTRACT:
Parkinson's disease (PD), more commonly referred to as just Parkinson's, is a chronic degenerative condition primarily affecting the motor system of the central nervous system. Parkinson's disease (PD) is associated with a group of disorders known as motor system problems, which result in unexpected or erratic bodily developments. There is progressive development of both motor and non-motor symptoms, greatly affecting one’s overall quality of life. While there is no cure, various treatments have been developed to help manage the symptoms of PD. The clinical characteristics of PD with emphasis on those features that differentiate the disease from other parkinsonian disorders. Current treatment approaches focus on symptom management, as there is no cure for PD. The mainstay of therapy includes medications that aim to increase dopamine levels or mimic its action, such as levodopa and dopamine agonists. Surgical interventions like deep brain stimulation (DBS) are used in advanced cases. Despite these treatments, disease progression is inevitable, leading to increasing disability over time.
Cite this article:
Pranjal A. Patil, Divakar R. Patil, Akash S. Jain, Azam Z. Shaikh, Sameer R. Shaikh, S. P. Pawar. A Review on Parkinson Disease. Research Journal of Science and Technology. 2025; 17(3):231-8. doi: 10.52711/2349-2988.2025.00032
Cite(Electronic):
Pranjal A. Patil, Divakar R. Patil, Akash S. Jain, Azam Z. Shaikh, Sameer R. Shaikh, S. P. Pawar. A Review on Parkinson Disease. Research Journal of Science and Technology. 2025; 17(3):231-8. doi: 10.52711/2349-2988.2025.00032 Available on: https://rjstonline.com/AbstractView.aspx?PID=2025-17-3-6
REFERENCE:
1. Pardo-Moreno, T.; García-Morales, V.; Suleiman-Martos, S.; Rivas-Domínguez, A.; Mohamed Mohamed, H.; Ramos-Rodríguez, J.J.; Melguizo-Rodríguez, L.; González- Acedo, A. Current Treatments and New, Tentative Therapies for Parkinson’s Disease. Pharmaceutics. 2023; 15: 770.
2. Elisabeth Dinter, Theodora Saridaki, Leonie Diederichs, Heinz Reichmann and Björn H. Falkenburger, Dinter et al. Translational Neurodegeneration. 2020; 9: 43.
3. Sarika Chaudhary, Nilika Tyagi, Department of Pharmacology, ITS College of Pharmacy, AKTU, India.
4. Dag Aarsland, Sven Påhlhagen, Clive G. Ballard, Uwe Ehrt and Per Svenningsson, Aarsland, D. et al. Nat. Rev. Neurol. 2012; 8: 35–47.
5. Doty, R. L. Nat. Rev. Neurol. 2012; 8: 329–339.
6. Melissa J. Armstrong,; Michael S. Okun. JAMA. 2020; 323(6): 548-560.
7. Parkinson's disease, Bloem, B.R.; Okun, M.S.; Klein, C. 2021, Article / Letter to editor (The Lancet (London). 2021; 397, 10291: 2284-2303.
8. Raghu S, Kothai R, Sankar V, Parkinson’s Disease-Review, J Res Med Dent Sci. 2020; 8 (6): 113-124.
9. Michael J. Zigmond: Departments of Neurology and Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. Robert E. Burke: Department of Neurology, Columbia University, New York, New York.
10. J Jankovic, Department of Neurology, Parkinson’s Disease Center and Movement Disorders Clinic, Baylor College of Medicine,6550 Fannin, Suite 1801, Houston, Texas 77030-3498, USA; josephj@bcm.tmc.edu.
11. Goutham Rao; Laura Fisch; Sukanya Srinivasan; et al. JAMA. 2003; 289(3): 347-353. http://jama.ama-assn.org/cgi/content/full/289/3/347
12. Lianna Marie, ttps://docs.lib.purdue.edu/purduepress_previews.
13. Margaret M. Hoehn. A-review-on-parkinsons-disease-overview-and-management- 3esoyrkq.
14. Philippe Rizek, Niraj Kumar, Mandar S. Jog . CMAJ Podcasts: Author interview at https://soundcloud.com/cmajpodcasts/151179-rev.
15. Thomas Fritsch, Kathleen A. Smyth, Maggie S. Wallendal, Trevor Hyde, Gary Leo and David S. Geldmacher, C D Marsden, Journal of Neurology, Neurosurgery, and Psychiatry 1994;57:672-681.
16. Günter Höglinger, German Parkinson’s Guidelines Committee and Claudia Trenkwalder, Höglinger et al. Neurological Research and Practice. 2024; 6: 30.
17. Lee TK, Yankee EL. A review on Parkinson’s disease treatment. Neuroimmunol Neuroinflammation. 2021; 8.
18. J Neurol Neurosurg Psychiatry: 10.1136/jnnp-2019-322338 on 23 June 2020. Downloaded from http://jnnp.bmj.com/ on August 28, 2024 by guest.
19. Radhakrishnan DM, Goyal V. Parkinson's disease: A review. Neurol India. 2018; 66: S26-35.
20. Janice M. Beitz, School of Nursing-Camden, Rutgers University, 311 N. 5th Street, Camden, NJ 08102.
21. Theresa A. Zesiewicz, Yarema Bezchlibnyk, Nicolas Dohse, Shaila Ghanekar, C. A. Davie. British Medical Bulletin, February 2008, 10.1093/bmb/ldn013.
22. Emamzadeh FN and Surguchov, A (2018) Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors. Front. Neurosci. 12:612.